Novartis Announces Positive Results From Phase III Study Of Iptacopan In IgA Nephropathy
2/10 07:59
(RTTNews) - Novartis (NVS) said that an investigational phase III study of iptacopan demonstrated clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy or IgAN. The company plans to review interim results with the FDA to...